Across TCGA pan-cancer cohorts, IGFL2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated IGFL2 data layer compared with 27 for mass-spec protein.

The strongest signal is observed in brain lower grade glioma (LGG), where higher IGFL2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IGFL2 expression acts as an unfavorable survival marker.

LGG, UCEC, and STAD are the cancer types where IGFL2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LGG	OS	Median	All	0.396	0.831	.017	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
STAD	DFS	Median	All	0.211	0.709	.015	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: IGFL2 tumor-vs-normal RNA expression · all IGFL2 data types